Category: Research
Preprint: SARS-CoV-2 may have originated as an infectious clone assembled in vitro
A new preprint out today finds that SARS-COV-2 has “a synthetic fingerprint unlikely to have evolved from its close relatives.” More...
Chimeric SARS-CoV-2 variant with a mortality rate of 80% *5 Updates*
Boston University scientists undertake a gain of function experiment and create a chimeric recombinant SARS-CoV-2 virus with 80% mortality rate in mice. More...
The world’s first XBB wave begins in Singapore
The world’s first wave of the recombinant SARS-CoV-2 variant XBB has apparently begun in Singapore. More...
USA: Florida recommends against males aged 18 to 39 receiving mRNA COVID-19 vaccines
“The State Surgeon General recommends against males aged 18 to 39 from receiving mRNA COVID-19 vaccines.” More...
Denmark: A soup of 120 Covid variants sequenced in one month
You may have heard the expression “a soup of Covid variants” recently.. More...
CDC: 81% of adults with Long Covid experience limitations in their daily activities
The US CDC has issued a new report on Long Covid showing the long term impact that the virus is having on some people. More...
XBB and three other SARS-CoV-2 strains found to be more antibody-evasive than BQ.1.1 and BA.2.75.2
The speed with which SARS-CoV-2 is now evolving is quite breathtaking – ever-fitter variants are now being uncovered on an almost daily basis. More...
Multiple hypermutated SARS-CoV-2 sequences that may have been created by molnupiravir
Molnupiravir, a drug used to treat SARS-CoV-2 infections, has received a lot of press attention since its launch, and not all of it has been positive. More...
Growth advantage for BQ.1.1 is above 100% per week
The Omicron variant BQ.1.1 appears to be in a prime position to drive the coming winter wave in Europe. More...
Preprint: Nuclear translocation of spike mRNA and protein is a novel pathogenic feature of SARS-CoV-2
A new preprint on Biorxiv looking at the nuclear translocation of S protein and mRNA in infected cells is attracting a lot of attention online today. More...